The pharma sector saw three biotechnology companies close financing rounds this week spanning neurodegenerative disease, radiopharmaceuticals, and inflammatory bowel disease.

The completed financing rounds reflect continued investor interest across a broad range of therapeutic modalities.

Violet Therapeutics closes $4.75 million seed extension

Violet Therapeutics has closed a $4.75 million seed extension led by Lifespan Vision Ventures, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures.¹ The proceeds are set to support Ind-enabling activities for the company's lead small molecule program targeting EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte signaling that emerged from Violet's proprietary Connect platform.

The Connect platform is designed to map disease-relevant cell-to-cell signaling interactions in the brain to identify therapeutically actionable pathways driving neuroinflammation, neurodegeneration, and synaptic loss.¹ Synaptic loss is among the strongest predictors of cognitive decline in Alzheimer's disease, and Violet's lead program targets glial-mediated synaptic preservation and repair as a core pathology.

"Preserving cognitive function is one of the most important challenges in aging biology, and Violet is approaching that challenge from a uniquely actionable angle," said Altar Munis, associate at Lifespan Vision Ventures. "The company's Connect platform gives it a systematic way to uncover how glial signaling contributes to synaptic dysfunction, with EphB3 representing a strong first step toward therapies that may protect brain health across aging and neurodegenerative disease."

Full-Life Technologies raises $150 million Series D

Full-Life Technologies has completed a $150 million financing package with approximately $110 million in Series D equity and $40 million in debt, led by Vivo Capital with participation from SK Biopharmaceuticals, Chengwei Capital, HSG, and other investors.² The funding round brings total funding to nearly $350 million since the company's inception in 2021.²

Proceeds are expected to advance two clinical-stage assets: [225Ac]-FL-020, a potential best-in-class actinium-based radiotherapeutic for prostate cancer, and [225Ac]-FL-261, a potential first-in-class candidate for multiple solid tumor indications.²

Both programs emerged from Full-Life's UniRDC discovery platform, and the company expects to have three differentiated clinical-stage programs by year-end 2026.

A significant portion of the capital is set to fund completion of a GMP-grade actinium-225 manufacturing facility in Belgium, a strategic differentiator in a field where isotope supply constraints have become a bottleneck for radiopharmaceutical development globally.²

Julie Wu, president and CFO of Full-Life, said: "With the strong momentum from our lead asset, and the rapid advancement of our pipeline assets, this funding will accelerate our transition toward late-stage development and ensure our Belgium GMP facility is fully operational to support global 225Ac commercial supply."

Accro Bioscience closes $50 million Series C

Accro Bioscience has closed a $50 million Series C financing led by OrbiMed, with participation from TCG Crossover, Lilly Asia Ventures, Cenova Capital, and existing investors Shenzhen Capital Group and Oriza Holdings.³ The proceeds will fund a Phase IIb clinical trial of AC-101, the company's lead RIPK2 inhibitor, for moderate-to-severe ulcerative colitis, as well as additional pipeline programs in immune-mediated diseases.

AC-101 targets the NOD/RIPK2 signaling pathway, a key mediator of intestinal inflammation whose dysregulation is implicated in UC and other autoimmune conditions. The drug has completed Phase I studies in healthy volunteers in Australia and China demonstrating a favorable safety and pharmacokinetic profile, and a Phase Ib/IIa proof-of-concept study in Chinese UC patients has been completed.

"We at Accro Bioscience are focused on our mission of delivering innovative oral treatments for the millions of patients living with immune mediated diseases," said Dr. Xiaohu Zhang, co-founder and CEO of Accro Bioscience. "I'm grateful to our investors who share our vision and have supported us continuously."

Sources

1. Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing LifeSpan Vision Ventures May 18, 2026 https://www.prnewswire.com/news-releases/lifespan-vision-ventures-leads-violet-therapeutics-4-75m-seed-extension-financing-302774963.html
2. Full-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities Full-Life Technologies May 18, 2026 https://www.prnewswire.com/news-releases/full-life-technologies-announces-us150-million-financing-to-accelerate-multiple-clinical-stage-assets-and-manufacturing-capabilities-302774873.html
3. Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases Accro Biosciences Inc. May 18, 2026 https://www.prnewswire.com/news-releases/accro-bioscience-announces-50-million-series-c-financing-led-by-orbimed-to-advance-clinical-pipeline-for-immune-mediated-diseases-302774824.html